We are the combination of four hospitals: the General Hospital, the Children’s Hospital, the Women’s Hospital and the Traumatology, Rehabilitation and Burns Hospital. We are part of the Vall d’Hebron Barcelona Hospital Campus: a world-leading health park where healthcare plays a crucial role.
Patients are the centre and the core of our system. We are professionals committed to quality care and our organizational structure breaks down the traditional boundaries between departments and professional groups, with an exclusive model of knowledge areas.
Would you like to know what your stay at Vall d'Hebron will be like? Here you will find all the information.
The commitment of Vall d'Hebron University Hospital to innovation allows us to be at the forefront of medicine, providing first class care adapted to the changing needs of each patient.
Pathological anatomy, Cross-departmental services
Liver tumours in children and adolescents can be benign and malignant. They are considered rare tumours (for every million children, only one will suffer from a malignant liver tumour), which is why they should be treated in centres with great experience in hepatic surgery, and ideally with a liver transplant programme for children. Additionally, they must have the latest advances in interventional radiology.
There are several types of tumour, which dictates prognosis and treatment. Malignant tumours, hepatoblastoma and hepatocarcinoma are the most frequent, accounting for 2/3 of all liver tumours. Benign tumours include haemangiomas, hamartomas and focal hyperplasia. In the case of benign tumours, especially those of a vascular nature (haemangiomas), vascular and interventionist radiology plays a decisive role, being able to avoid unnecessary surgical procedures, improving the prognosis and avoiding liver transplants.
Surgical treatment is an essential part of the cure of most malignant cases, and liver transplants can be the only possibility for curing some patients. Interventional radiology techniques also play an important role. Vall d’Hebron Hospital has gained considerable experience in treating these tumours and is involved in the first global study to treat hepatic malignant tumours for children (PHITT), being one of the reference centres for this pathology in Spain within the European ERN networks.
Patients usually present with abdominal distension, a palpable abdominal mass, or both. Weight loss, non-focus fever and loss of appetite are also common. Sometimes they can also be discovered incidentally when performing an ultrasound for another reason. If there is any accompanying liver disease or the bile duct is compressed, a yellowish colouration of the skin and mucous membranes (jaundice) may appear. Some patients may present with abdominal pain.
It can affect children of any age, even newborns. Tumour types are different at the different stages of life (newborns, young children and adolescents). Haemangiomas (benign tumours) are more frequent in premature children. Some malignant tumours are associated with liver and metabolism diseases, as well as genetic and hereditary syndromes or with vascular anomalies.
The tumour is generally detected by the primary care paediatrician, who will refer the patient for evaluation. Diagnoses can sometimes be established in a prenatal ultrasound or shortly after birth. Lastly, it can be detected in routine clinical controls in children with illnesses related to the development of these tumours. When the patient presents a malignant tumour, it will be important to complete the study of possible syndromes and related diseases.
It depends on the type of tumour. In benign cases, it may consist of image controls, include pharmacological treatments or interventional radiology, and reserving surgery for very specific cases. In malignant tumours, surgery is essential for curing the patient and will be accompanied in general by chemotherapy treatment, which is administered before or after the intervention. In very advanced cases, liver transplants will be necessary.
Blood tests with tumour markers, an abdominal ultrasound and a magnetic resonance imaging scan are normally carried out. In order to plan surgery, it is usually necessary to carry out a CT scan. When there is a suspicion of malignancy, a chest CT will also be done and a small sample of tissue will be taken to know the exact tumour type.
Unfortunately, there are no preventive measures. Unlike liver tumours in adults, closely related to the consumption of alcohol and viral infections (hepatitis), in children they are generally isolated cases. Only a small percentage of cases appear in children with illnesses and syndromes that predispose to their appearance, such as bile ducts atresia or some metabolic diseases, in which it is essential to monitor them so that, if they appear, they can be detected early.
Cutaneous melanoma is a malign tumour located on the skin, usually black or coffee coloured. Some of the main risk factors include exposure to sunlight and freckles. They can develop on any part of the skin, but they are more frequent on men's chests and backs and women's legs. They are responsible for 65% of deaths due to skin cancer. Discovering and treating the illness in time is vital for stopping it spreading to other parts of the body.
Cutaneous melanoma is a cancer that originates in cells known as melanocytes. These cells produce melanin, which is why the tumours are usually coffee coloured or black, but they can also be pink, pale coloured or white. Overall, cutaneous melanomas represent approximately 1% of all tumours in both sexes, and every year 15 out of every 100,000 people are diagnosed, a figure that is increasing in nearly all European countries.
Cutaneous melanomas can develop on any part of the skin, but they are more frequent on the chest and back in men and the legs in women. The neck and face are other common sites. Having skin with a dark pigmentation reduces the risk of melanoma in these more common locations.
Melanomas are much less frequent than other types of skin cancer, but they are more dangerous, because they grow more quickly and they are very likely to spread to other parts of the body if they are not discovered and treated in time.
The first signs of a melanoma are as follows:
Melanomas do not always start with a freckle: they can also appear on normal-looking skin and can form on any part of the body. They very often appear on parts of the body that have been exposed to the sun, such as a person’s back, legs, arms or face. They can also occur on parts that have little exposure to sunlight, such as the soles of the feet, the palms of the hands and in the nail beds. These hidden melanomas are more frequent in people who have darker skin.
In Spain, the condition especially affects women, with an average initial-diagnosis age of 55, and men at an average age of 57. For white individuals, the incidence of cutaneous melanoma is increasing at an alarming rate, in all Cancer Registries. In Europe, it is the ninth most frequent cancer, with around 200,000 cases diagnosed every year. Although it only represents between 1.5 and 1.7% of skin cancers, it is responsible for 65% of deaths from skin cancer. This figure is stable in spite of the increased incidence, probably because of early diagnosis, which is the most important factor, and improvements in treatment.
The reason why melanoma occurs is unclear, although some risk factors have been identified, which should be taken into account:
It is usually diagnosed after observing a suspect freckle that presents alterations known as (1,2,3,4):
For this reason, if a new, unusual freckle is found, or a change is noted in an existing one, it should always be examined by a dermatologist, as early diagnosis is vital in this illness. The tests and procedures used to diagnose cutaneous melanoma include the following:
The recommendations for treatment depend on many factors, such as the thickness of the primary melanoma, the possibility that the cancer has spread or the presence of specific genetic changes in the melanoma cells, among others.
However, surgery is the main treatment against local and regional melanoma. It may also be an option for combating metastatic melanoma. If surgery is not an option, the melanoma can be called “unresectable”. In order to recommend a specific treatment plan, the doctors will take into account the state of the illness and the risk of relapse in each person. Subsequently, in accordance with the state, a systematic treatment can be indicated for a period of one year. In recent years, the treatment of melanomas that have spread extensively through the body has changed, as the newest forms of immunotherapy and targeted drugs have proven to be more effective than chemotherapy.
A complete physical examination must be conducted, including a general examination of the skin. The purpose of these tests is to identify risk factors and signs or symptoms that may indicate that the melanoma has spread beyond the original site. For most low-risk melanomas, less than 1 mm thick, it is generally unnecessary to carry out an additional search for metastasis or spreading.
In the case of people with high-risk melanoma, more exhaustive tests may be considered, including the following:
- Limiting exposure to ultraviolet rays.
- Avoid tanning booths.
- Protect children from the sun, to avoid sunburn.
- Pay attention to unusual freckles when examining your skin. If in doubt, it is always a good idea to make an appointment with a dermatologist, for a thorough check up.
The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”. Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health). Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information. Legal basis: Consent of the data subject. Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen. Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time. Source: The data subject. Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.